InvestSMART

AdAlta Limited (ASX:1AD)

ALERT: Price-sensitive ASX Announcement for 1AD
Current share price for 1AD : $0.003 0 (0%)+
Announcement
Release
1 Jul 2026 9:03AM
Price at Release
$0.003
Full Release
download
Summary
AdAlta Limited (ASX:1AD) has announced a milestone payment of US$1 million to their co-development partner, Shanghai Cell Therapy Group Co Ltd, under their Development and Collaboration Agreement for the CAR-T cell therapy BZDS1901, which is being developed for advanced mesothelioma. This payment, funded partly from a recent A$2.5 million placement, grants AdAlta access to new clinical data from Chinese trials and secures critical manufacturing materials necessary for producing BZDS1901 in Australia. This marks the completion of AdAlta's initial financial commitments, allowing them to advance their manufacturing capabilities in Australia and prepare for US FDA engagement, all part of their 'East to West' strategy.
Key Points
  • AdAlta made a US$1 million milestone payment to Shanghai Cell Therapy Group.
  • The payment covers five additional mesothelioma patients treated in China.
  • New clinical data and manufacturing materials are secured.
  • AdAlta completed initial financing obligations for BZDS1901 development.
  • Focus shifts to Australian manufacturing and US FDA engagement.
  • The strategy aligns with AdAlta's 'East to West' business approach.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.